Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV F Vaccine Dose-Ranging Study in Women
NCT01960686Phase 2Completed
- Sponsor
- Novavax
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RSV F vaccine + aluminum phosphate in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Novavax. Primary endpoints: Serum IgG antibody titers specific for the F-Protein antigen and Assessment of Safety. Started Oct 2013; status: completed.
02
Drugs
RSV F vaccine + aluminum phosphate
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT01960686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960686.